Tinzaparin sodium
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).
n = 1 to 25, R = H or SO3Na, R1 = H, SO3Na or COCH3, R2 = H and R3 = COONa or R2 = COONa and R3 = H | |
| Clinical data | |
|---|---|
| Trade names | innohep(R) |
| AHFS/Drugs.com | Monograph |
| Routes of administration | subcutaneous (once daily) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 90% for Anti-Xa activity, 67% for Anti-IIa activity) |
| Metabolism | minor metabolisation in liver by desulfation and/or depolymerization; excretion via kidneys in almost unchanged form |
| Elimination half-life | 200 min. for Anti-Xa activity, 257. min for Anti-IIa activity |
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.110.590 |
| Chemical and physical data | |
| Molar mass | 6500 g/mol (average) |
| (what is this?) (verify) | |
It can be given subcutaneously by syringe, or intravenously. It was manufactured by Leo pharmaceutical company, who withdrew the product from the US in 2011 due to low sales and a contamination issue.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.